EXICURE, INC. Increase (Decrease) in Unbilled Receivables
EXICURE, INC. (XCUR) reported Increase (Decrease) in Unbilled Receivables of $11.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-06.
Discontinued › Notes
us-gaap:IncreaseDecreaseInUnbilledReceivables · last filed 2018-08-06
- EXICURE, INC. increase (decrease) in unbilled receivables for the quarter ending 2018-06-30 was $19.00K, a 24.00% decline year-over-year.
- EXICURE, INC. increase (decrease) in unbilled receivables for the quarter ending 2018-03-31 was -$8.00K, a 101.78% decline year-over-year.
- EXICURE, INC. increase (decrease) in unbilled receivables for the quarter ending 2017-12-31 was -$188.00K.
- EXICURE, INC. increase (decrease) in unbilled receivables for the quarter ending 2017-09-30 was -$273.00K.
- EXICURE, INC. increase (decrease) in unbilled receivables for fiscal 2017 was $13.00K.
- EXICURE, INC. increase (decrease) in unbilled receivables for fiscal 2016 was -$237.00K.
| Period end | Increase (Decrease) in Unbilled Receivables 3 month | Increase (Decrease) in Unbilled Receivables 6 month | Increase (Decrease) in Unbilled Receivables 9 month | Increase (Decrease) in Unbilled Receivables 12 month |
|---|---|---|---|---|
| 2018-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $11.00K 10-Q · filed 2018-08-06 | -$177.00K derived: sum of 3 quarters · filed 2018-08-06 | -$450.00K derived: sum of 4 quarters · filed 2018-08-06 |
| 2018-03-31 | -$8.00K 10-Q · filed 2018-05-15 | -$196.00K derived: sum of 2 quarters · filed 2018-05-15 | -$469.00K derived: sum of 3 quarters · filed 2018-05-15 | -$444.00K derived: sum of 4 quarters · filed 2018-08-06 |
| 2017-12-31 | -$188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$461.00K derived: sum of 2 quarters · filed 2018-03-09 | -$436.00K derived: sum of 3 quarters · filed 2018-08-06 | $13.00K 10-K · filed 2018-03-09 |
| 2017-09-30 | -$273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$248.00K derived: sum of 2 quarters · filed 2018-08-06 | $201.00K 10-Q · filed 2017-11-14 | $201.00K derived: sum of 4 quarters · filed 2018-08-06 |
| 2017-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $474.00K 10-Q · filed 2018-08-06 | $474.00K derived: sum of 3 quarters · filed 2018-08-06 | |
| 2017-03-31 | $449.00K 10-Q · filed 2018-05-15 | $449.00K derived: sum of 2 quarters · filed 2018-05-15 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$237.00K 10-K · filed 2018-03-09 | ||
| 2016-09-30 | -$237.00K 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |